Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Chise Profile picture
@sailorrooscout
Apr 8, 2021 • 9 tweets • 5 min read • Read on X
Scrolly
Encouraging studies! 🧵
An analysis of cross-reactive viral binding and neutralization of emerging SARS-CoV-2 variants shows Novavax’s and Moderna’s vaccines elicit immune responses that are effective against variants B.1.429 (CA) and B.1.351 (S. Africa).
nejm.org/doi/full/10.10…
Patients previously infected with SARS-CoV-2 received Pfizer’s vaccine. Before vaccination, they had neutralizing activity against variants B.1.1.7 & P.1 but not B.1.351. AFTER one dose, neutralizing activity against ALL variants increased substantially!
nejm.org/doi/full/10.10…
Convalescent serum from those who recovered from an infection with SARS-CoV-2 variant B.1.351 showed potent neutralization of D614G (original), as well as variants B.1.351 (S. Africa) AND P.1 (Brazil). Booster vaccines may just seal the deal if needed!
nejm.org/doi/full/10.10…
3 weeks after a single dose, those with recent SARS-CoV-2 infection or seropositive status had higher levels of antibody to 4 SARS-CoV-2 antigens and higher levels of antibodies with neutralizing characteristics than those without a history of infection.
nejm.org/doi/full/10.10…
Moderna’s vaccine significantly reduces neutralizing activity against VOCs B.1.1.7 (UK), B.1.1.7+ E484K, P.1 (Brazil), B.1.351 (S. Africa) AND B.1.427/B.1.429 (CA).
nejm.org/doi/full/10.10…
Data from a UK clinical study suggests the AstraZenecas vaccine is 70.4% effective against symptomatic COVID-19 caused by variant B.1.1.7. The vaccine was 81.5% effective in preventing symptomatic COVID-19 caused by non-B.1.1.7 strains.
thelancet.com/journals/lance…
Antibody titers of vaccinees who recovered from a previous SARS-CoV-2 infection were found to be 10x to 45x as high as those of vaccinees without preexisting immunity at the same time points after just one dose of either mRNA vaccine.
nejm.org/doi/full/10.10…
Serum samples obtained from participants vaccinated with two doses of Pfizer’s BNT162b2 COVID-19 vaccine shows effective neutralization against VOCs B.1.1.7 (UK), B.1.351 (S. Africa) AND P.1 (Brazil).
nejm.org/doi/full/10.10…
Why is this all good news? Because the vaccines are effective! This thread includes something on just about each of them. These also don’t even take into account cell-mediated immunity/ my love of T-cells which add a whole other layer of protection!

Have a great day! ☀️🧬🦠🧫💉

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Chise

Chise Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

Chise Profile picture
Oct 28, 2024
THIS IS HUGE! An HIV PrEP drug candidate in the form of a twice-yearly subcutaneous injection has been shown to reduce HIV infections by 96% in a SECOND late-stage Phase III trial. Lenacapavir was 99.9% effective at preventing HIV in MORE THAN 2,000 participants.🧵⬇️
Source:
• gilead.com/news/news-deta…Image
These results come from the PURPOSE 2 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in individuals aged 16 years or older. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the brand name Sunlenca for use alongside other
Read 13 tweets
Chise Profile picture
Oct 24, 2024
So, not COVID related BUT, this is REALLY exciting news. Phase I/II data shows Moderna’s Norovirus vaccine candidate mRNA-1403, has shown early signs of efficacy AND elicited robust serum HBGA-blocking antibody responses against ALL THREE NoV genotypes. Let’s talk about that!🧵⬇️
At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomized, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections.
As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden. Symptoms include vomiting and diarrhoea, which can be severely dehydrating, and the risk of severe outcomes from NoV is greatest in young children and older
Read 16 tweets
Chise Profile picture
Oct 21, 2024
THIS IS HUGE! Researchers at JHU have developed an experimental drug called RK-33, that in preclinical studies has shown promise in treating breast cancer with bone metastases. RK-33 eliminated the metastases AND prevented further cancer spread. Let’s talk about that!🧵⬇️
The research has been published in Cancer Letters. Yes, it is PEER-REVIEWED.
• sciencedirect.com/science/articl…Key Takeaways: •RK-33 targets DDX3, an RNA helicase elevated in cancer cells, to inhibit breast cancer bone metastasis. •In mouse models, RK-33 eliminated bone metastases and prevented further cancer spread without significant adverse effects. •The study suggests RK-33 as a promising treatment for breast cancer bone metastasis, urging further research into its broader applications.
In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously shown to help treat other types of cancer and viral illnesses.
Read 14 tweets
Chise Profile picture
Oct 17, 2024
THIS IS HUGE! Researchers at Lancaster University have developed RI-AG03, a peptide inhibitor, that in preclinical studies PREVENTED the build-up of harmful Tau proteins in the brain, which are believed to be a key driver of Alzheimer’s disease. Let’s talk about that! 🧵⬇️
The research has been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Yes, it is PEER-REVIEWED.
•~ alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…What You Need to Know ⬇️ •Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease. •The drug, a peptide inhibitor called RI-AG03, successfully prevented the build-up of toxic tau proteins in both laboratory and fruit fly studies. •Although further research is necessary, including clinical trials in humans, this research contributes to the advancement of more effective therapies for neurodegenerative diseases. •There are two main “hotspots” on the tau protein, where fibril clumping occurs. In this new study, research...
Tau proteins are essential for maintaining the structure and function of neurons. However, in Alzheimer’s disease, these proteins malfunction and aggregate into long, twisted fibrils. As these fibrils build up, they form neurofibrillary tangles- masses of tangled tau proteins
Read 15 tweets
Chise Profile picture
Oct 9, 2024
THIS IS HUGE! Researchers at the University of Pennsylvania have developed a vaccine against the bacterium Clostridioides difficile (C.diff), that in preclinical studies, protected against succumbing from infection AND prevented recurring cases. Let’s talk about that! 🧵⬇️
The study has been published in Science. Yes, it is PEER-REVIEWED.
• science.org/doi/10.1126/sc…Model figure. (A) C. difficile toxins target the intestinal epithelium and cause severe pathology and gastrointestinal disease leading to morbidity and mortality. (B) When vaccinated mice are infected with C. difficile, anti-toxin IgG and IgA protect mice from disease and inclusion of PPEP-1 and CdeM as immunogens improves decolonization of toxigenic C. difficile from the gastrointestinal tract. Credit: Science (2024). DOI: 10.1126/science.adn4955
The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a million people in the U.S. contract C. diff every year, often from hospitals-
Read 15 tweets
Chise Profile picture
Oct 5, 2024
THIS IS HUGE! Scientists at the University of Oxford are developing the world's FIRST ovarian cancer vaccine that could potentially wipe the disease out. OvarianVax teaches the immune system to recognize and attack the earliest stages of ovarian cancer. Let’s talk about that!🧵⬇️
The hope is that individuals could receive the vaccine preventatively with the goal of eradicating the disease. Researchers have suggested it could work in a similar way to the human papillomavirus (HPV) vaccine, which is on track to stamp out cervical cancer.
Oxford researchers are designing OvarianVax, a vaccine which teaches the immune system to recognize and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(